Straus Michele M, Ghitza Udi E, Tai Betty
Center for the Clinical Trials Network, National Institute on Drug Abuse, National Institutes of Health, United States Department of Health and Human Services, Bethesda, MD, USA.
Subst Abuse Rehabil. 2013 Sep 2;2013(4):65-72. doi: 10.2147/SAR.S47463.
The opioid overdose epidemic is an alarming and serious public health problem in the United States (US) that has been escalating for 11 years. The 2011 National Survey on Drug Use and Health (NSDUH) demonstrated that 1 in 20 persons in the US aged 12 or older reported nonmedical use of prescription painkillers in the past year. Prescription drug overdose is now the leading cause of accidental death in the United States - surpassing motor vehicle accidents. Great efforts have been initiated to curb the overdose crisis. Notable examples of these efforts are (1) the Drug Enforcement Administration's (DEA) National Take-Back Initiative instituted in 2010; (2) the Prescription Drug Monitoring Programs (PDMPs) implemented in most US states to provide practitioners with point-of-care information regarding a patient's controlled substance use; (3) the naloxone rescue programs initiated in the community to avert mortality resulting from overdose. The use of naloxone rescue strategies has gained traction as an effective measure to prevent fatal opioid overdose. Many US federal-government agencies are working to make these strategies more accessible to first responders and community participants. This new approach faces many challenges, such as accessibility to naloxone and the equipment and training needed to administer it, but none is more challenging than the fear of legal repercussions. US federal-government agencies, local governments, health care institutions, and community-based organizations have begun to tackle these barriers, and naloxone take-home programs have gained recognition as a feasible and sensible preventive strategy to avoid a fatal result from opioid overdose. Although many challenges still need to be overcome, it is important for federal government research agencies to initiate and support independent and rigorous evaluation of these programs to inform policymakers how effective these programs can be to save lives and curb the opioid overdose public health crisis.
阿片类药物过量流行是美国一个令人担忧且严重的公共卫生问题,该问题已持续升级11年。2011年全国药物使用和健康调查(NSDUH)表明,在美国12岁及以上人群中,每20人中有1人报告在过去一年中曾非医疗使用处方止痛药。现在,处方药过量是美国意外死亡的首要原因——超过了机动车事故。已经展开了巨大努力来遏制过量危机。这些努力的显著例子包括:(1)2010年美国缉毒局(DEA)发起的全国回收倡议;(2)美国大多数州实施的处方药监测计划(PDMPs),为从业者提供有关患者受控物质使用情况的即时医疗信息;(3)社区发起的纳洛酮急救计划,以避免过量导致的死亡。纳洛酮急救策略的使用已成为预防致命阿片类药物过量的有效措施。许多美国联邦政府机构正在努力使这些策略更容易被急救人员和社区参与者获取。这种新方法面临许多挑战,如纳洛酮的可及性以及给药所需的设备和培训,但没有比担心法律后果更具挑战性的了。美国联邦政府机构、地方政府、医疗机构和社区组织已经开始应对这些障碍,纳洛酮带回家计划已被认可为一种可行且合理的预防策略,以避免阿片类药物过量导致致命后果。尽管仍有许多挑战需要克服,但联邦政府研究机构启动并支持对这些计划进行独立且严格的评估非常重要,以便告知政策制定者这些计划在挽救生命和遏制阿片类药物过量公共卫生危机方面的效果如何。